What’s New With Cannabis Stocks for the Week Ending 05/28/21

The cannabis industry is slowly developing into a full-fledged sector, and more and more states are legalizing the use of medical and/or recreational marijuana. The Cannabis Stock Report is your guide to the following issues:

Cannabis stocks have been having a good week so far, and the industry is beginning to look more promising after the Trump administration urged the DEA to allow more research into the benefits of medical marijuana.

Pot stocks are soaring this week as the trend continues for marijuana stocks is up this week. The Dow Jones Industrial Average, the S&P 500, and the Nasdaq are all up in response to the Trump administration’s decision to allow sales of recreational pot in states.

Summary

  • Ohio’s medical cannabis program has experienced accelerated growth.
  • Health Canada has added 3 licenses, bringing the total number of licenses to 677.
  • Over the past year, 420 Investor’s model portfolios have increased 58.6% to 88.5%, while the Global Cannabis Stock Index has increased 34.2%.

Overview Congressman Nadler introduced the MORE Act of 2021. The Florida Supreme Court affirmed the lower court’s 2020 decision that the vertical integration requirement remains in effect. Weekly sales of medical cannabis in Ohio exceed $5 million. Health Canada added 3 licences, bringing the total number of licences to 677, including 2 expired, revoked or suspended licences. I shared this information with 420 subscribers of Investor this week:

  • Composition of the model portfolio 21.05.21
  • Cannabis Subsector Review – 05/21
  • Preliminary financial statements of Canopy Growth and Harborside
  • The marijuana monster continues his execution

Here are some of the most notable names on this week’s 420 Investor Focus List:

  • CBA establishes a Science and Innovation Group that will deal with intellectual property related to genetics and biosynthesis.
  • CRLBF’s first quarter revenues exceeded expectations, increasing 10% from the previous quarter to $179 million and adjusted EBITDA of $35 million.
  • GNLN has announced that its forthcoming acquisition of KushCo has passed the HSR review after a waiting period.
  • GRWG announces acquisition of two stores in California
  • DHHS opens its 10th. Pennsylvania Branch
  • KSHB announced that its upcoming acquisition by Greenlane has passed the HSR test after a waiting period.
  • In the first quarter, PLNHF’s revenues increased 42% to $23.8 million and adjusted EBITDA was $5.2 million.
  • TCNNF announced the upcoming opening of its first cannabis store in Massachusetts at 3rd. June.
  • TLLTF announced that Airo Brands was a customer for bottled vape products in Pennsylvania. The company reported revenue of $46.8 million and adjusted EBITDA of $6.2 million for the first quarter.
  • UGRO has approved a $5 million share buyback program.

The global cannabis stock index rose for the second week in a row and ended the month down, but well off its lows. The index closed at 59.57, up 7.7%: Theindex, which lost 34.1 percent in 2019 and 54.9 percent in 2018 after rising 91.8 percent in 2017 and 88.8 percent in 2016, rose 5.2 percent in 2020. For 2021, it is up 34.2%. It currently has 46 shares and ended 2020 at 44.39 : word-image-12967 Examples of portfolios word-image-12968 420 Investor offers subscribers three model portfolios, two of which are long-term and fully invested to beat the Global Cannabis Stock Index, 420 Opportunity and 420 Quality. 420 Opportunity ended the week with an estimate of $176,717, up 8.5%. The model portfolio increased 67.7% in 2021, 35.6% in 2020 and 253.4% since April 2014. 420 Quality ended the week at $256,203, up 8.8% over the week and 58.6% in 2021 after up 42.8% in 2020. Launched in March 2017, the model is designed for long-term investors looking to invest in leading cannabis stocks with low portfolio turnover. Since its inception, it has gained 412.4%, compared to an index decline of 26.3%. Flying High, which focuses on swing trading, ended the week at $475,864, up 10.2%. The model portfolio is 52.7% in 2020 and 88.5% in 2021, with a return of 4659% since inception in late 2013. Outlook After a strong recovery in early 2019, the cannabis sector fell sharply to unprecedented levels the following year due to several negative events, including the CannTrust scam, the unexpected resignation of Bruce Linton as CEO of Canopy Growth, a disappointing start to legalization in Canada, regulatory confusion in the US regarding CBD and a slow start to legalization in California, the vaping crisis, and then the financial turmoil and market disruption caused by the COVID-19 pandemic. In the industry, the capital available to fund expansion has dried up, a situation that continues to put heavy pressure on companies with negative cash flow, as the availability of capital is constrained by stronger market participants. Cannabis shares overreacted and reached their lowest level in March 2020. Today they benefit from the perception that the sector offers good growth prospects, which was not the case then. One important change is that the pandemic has forced many regulators to ban previously prohibited retail activities, such as B. to allow home pickup and delivery. The legal market is growing rapidly and is becoming even more convenient than the illegal market because orders can be placed online. High unemployment and large deficits have fueled states’ legalization efforts, as have more favorable regulatory controls at the local level. Access to capital has improved dramatically and large companies are generating significant and rapidly growing revenues and profits. There are several potential catalysts, including the FDA providing clarity on CBD regulation, the progress of legalization in Canada that began in October 2018 and is gradually covering a wider range of products, and the continued growth of German and Israeli MMJ and other international markets that have been slow to develop. Implementation in California and Massachusetts for adults has been slow, but there are already significant improvements. Michigan and Illinois legalized adult-use drugs in late 2019, and those markets are showing strong growth that could prompt other states to legalize. Voters in Arizona, Montana, South Dakota and New Jersey approved adult drug legalization in November, and New Mexico, New York and Virginia introduced legalization in the legislature in 2021. Key issues in the future are likely to include continued cross-industry investment in the sector and further consolidation in Canada and the United States, possible federal regulatory reform (the SAFE Bank Act and other broader legislation that could eliminate the 280E tax and allow co-ops to trade on higher exchanges, as well as the widespread use of credit cards to purchase cannabis) measures to enable cannabis research, the introduction of MMJ in Germany, Mexico, and Australia, continued progress in South America, and the possible legalization of adult-use cannabis in Israel and Mexico the introduction of new legal cannabis in AZ, MT, NJ, and SD, the introduction of MMJ in AL, WV, and VA, the possible legalization by legislators in CT, DE, FL, MD, MN, NH, PA, and RI, and the introduction of commercial programs in NM, NY, and VT in 2022 and in VA in 2024. Stay ahead of the crowd by subscribing to 420 Investor, the largest and most comprehensive subscription service for cannabis dealers and investors since 2013. word-image-12969 word-image-12970 Based in Houston, Alan draws on his experience as founder of the 420 Investor online community, the first and still largest integrated analysis platform focused on publicly traded cannabis stocks. Through his many connections in the cannabis community, Alan continues to find new ways to bring the industry together and promote sustainable growth. At New Cannabis Ventures, he is responsible for content development and strategic alliances. Until early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent analyst and then for more than two decades in research and portfolio management. Alan is a prolific writer with over 650 articles published on Seeking Alpha since 2007, where he has 70,000 subscribers. He is a frequent speaker at industry conferences and appears regularly in the media, including the NY Times, Wall Street Journal, Fox Business and Bloomberg TV. Get in touch with Alan: Twitter | Facebook | LinkedIn | E-mail

 

In this section:

ACB, Aurora Cannabis, cl, Cresco Labs, CRLBF, gnln, greenlane, GrowGeneration, GRWG, HARV, Harvest Health and Recreation, HRVSF, kshb, KushCo Holdings, Planet 13, PLNHF, PLTH, tcnnf, TILT, Tilt holdings, TLLTF, TRUL, trulieve, ugro, urban-gro

revenue for 1Q13 increased 42% to $23.8 million

Cresco Labs’ first quarter revenue increased 169% to $178 million

Strong growth in the cannabis sector helped TILT Holdings increase first quarter revenue 15% to $46.8 million

Greenlane and KushCo Holdings expect the merger to be completed in the third quarter following the expiration of the HSR

The cannabis industry is experiencing a boom, with both companies and people jumping into the fray. With a new administration in office, it’s uncertain how this industry will change, but for the moment, we are seeing increased demand from both the public and investors. Cannabismouth.com has a free website for investors who want to take a look at the current cannabis industry.. Read more about global cannabinoids stock and let us know what you think.

420 investor complaintscbd indexvertical cos. stockbgcang newsu.s. mso comparison420 packaging stock,People also search for,Privacy settings,How Search works,u.s. mso comparison,420 packaging stock,nici stock price,global cannabinoids stock,ncv media,420 investor portfolio,global cannabinoids stock price,cbd stocks to watch